GSK shares leap 5% as results top forecasts and guidance is upgraded! Can they keep rising?
Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains. The post ...
GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion
GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company ...
TMCnet2h
GSK plc. (GSK) Investors Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GSK PLC. (GSK), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
FiercePharma9h
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook
GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.
TMCnet4h
Securities Fraud Investigation Into GSK plc. (GSK) Announced - Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announces an investigation of GSK plc. ("GSK" or the "Company") (NYSE: GSK) on behalf of investors concerning the Company's possible violations of federal securities ...
Investors Chronicle13h
GSK bounces back on better outlook and share buybacks
GSK’s lead in vaccines is a cause for concern after mixed political signals in the US, with ardent vaccine sceptic Robert F Kennedy Jr vowing a clampdown on the pharmaceutical industry, which partly ...
FTSE 100 movers: GSK surges on guidance; DCC in the red
Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...
FTSE 100 Live 05 February: Gold at new high, GSK lifts long-term sales outlook
The increase comes as investors continue to hedge against geopolitical risks, particularly on fears over the impact of a ...
Investing16h
GSK Navigates Vaccine Setbacks With Strong Cash Flow and Expanding Pipeline
GSK (LON: GSK) has issued an update which inevitably reflects the difficulties faced in the last year, while also providing a host of reasons to be more upbeat on future prospects. Concerns over the ...
CFRA cuts GlaxoSmithKline stock price target to $40, maintains hold
CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...